Inside Processa Pharma: CEO George Ng on Disrupting Oncology Drug Development
Jul. 14, 2025
Processa Pharmaceuticals (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of existing FDA-approved oncology therapies, resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa's strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
Processa is a client of RedChip. Visit www.redchip.com/stocks/pcsa to learn more.
